Piper Sandler maintains RxSight at Neutral, lowers price target to $8 from $10

What happened

Piper Sandler kept its rating on RxSight at Neutral but lowered its price target to $8 from $10. The revised target is a 20.0% decrease and implies 74.3% upside from RxSight’s November 3 closing price of $4.59.

Confirmed

Global impact / market context

The lower target signals that Piper Sandler sees less potential value for RxSight than before, while retaining a Neutral rating. If other analysts or investors respond similarly, expectations could weigh on the stock; the stated target still remains above the cited closing price.

Analyst inference

This is an analyst assessment, not a reported change in RxSight’s operations, sales, costs, or cash available. Its direct relevance is to expectations and investor positioning: the target was cut, but the Neutral rating was unchanged and the target remains above the cited close.

Analyst inference

What to watch

1. Check whether Piper Sandler changes its Neutral rating or $8 target again, since either would indicate a shift in the analyst’s view of RxSight. Analyst inference
2. Look for new company information on sales, costs, or business plans; the article reports no operating update to explain the lower target. Analyst inference
3. Compare later analyst assessments with the unchanged Neutral rating and the $8 target, while treating the cited 74.3% upside as an estimate, not a guaranteed return. Analyst inference

Evidence

• Original source link unavailable